

SEPTEMBER 12 – 15, 2026
SEOUL, REPUBLIC OF KOREA

Correspondence: *yxia@zju.edu.cn*

RESULTS

EGFR+BRAF±MEK blockade offers meaningful clinical activity and superior benefit over BRAF+MEK inhibition, with a notable safety burden that requires close monitoring, whereas exploratory analyses of subsequent-line therapy after progression on BRAF-directed treatment, adding immunotherapy to chemotherapy did not show a clear incremental benefit.